Satya Kuchimanchi

Satya joined Triplet Therapeutics, Inc. in January 2020 as Vice President, CMC. He has over 20 years of experience in oligonuceleotides, covering siRNA, aptamers and antisense platforms. Prior to joining the company, Satya was at Alnylam for 12 years, initially in R&D, leading the high throughput synthesis group, RNA lead development, and later as Director, Process Sciences, responsible for drug substance process characterization and pre-validation activities for late stage clinical programs. At Alnylam, Satya played a key role in RNAi chemistry platform development for multiple early and late stage programs including research to launch of two approved siRNA drugs, ONPATTRO, a treatment for TTR Amyloidosis and GIVLAARI, a treatment for Acute Hepatic Porphyrias. Prior to Alnylam, Satya was at Avecia Biotechnology, a CMO specialized in the GMP manufacture of Oligonucleotide therapeutics. Satya has a Ph.D. in Organic Chemistry from Indian Institute of Chemical Technology, Hyderabad, India and post-doctoral fellowships from University of Montpellier, Montpellier, France and Vanderbilt University, Nashville, TN.